Overview

A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of escitalopram treatment in participants with severe major depressive disorder (MDD [marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation]).
Phase:
Phase 4
Details
Lead Sponsor:
Xian-Janssen Pharmaceutical Ltd.
Treatments:
Citalopram
Dexetimide